Remibrutinib - Novartis
Alternative Names: LOU-064; LOU064-NXA; NVP-LOU064-NXALatest Information Update: 05 Feb 2025
Price :
$50 *
At a glance
- Originator Novartis
- Class Amines; Anti-inflammatories; Antiallergics; Antiasthmatics; Benzamides; Cyclopropanes; Ethers; Fluorobenzenes; Pyrimidines; Skin disorder therapies; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic urticaria; Hidradenitis suppurativa; Multiple sclerosis
- Phase II Peanut hypersensitivity
- Discontinued Asthma; Atopic dermatitis; Sjogren's syndrome
Most Recent Events
- 29 Jan 2025 Phase-III clinical trials in Hidradenitis suppurativa in Australia (PO) (NCT06799000)
- 23 Dec 2024 Novartis Pharmaceuticals plans phase-III RELIEVE trial for Myasthenia gravis (Adjunctive treatment) in December 2024 (PO, Tablet) (NCT06744920)
- 30 Oct 2024 Novartis intends to submit regulatory application for Chronic inducible urticaria in 2027 or beyond